Allogene Stock Analysis

ALLO -  USA Stock  

USD 11.36  0.22  1.90%

The latest slide in stock price could raise concerns from institutional investors as the firm it trading at a share price of 11.36 on very low momentum in volume. The company directors and management have failed to build on market volatilities in December. However, diversifying your overall positions with Allogene Therapeutics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.02. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Allogene Therapeutics partners.
Please continue to Trending Equities.

Allogene Stock Analysis 

The Allogene Therapeutics stock analysis report makes it easy to digest most publicly released information about Allogene Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Allogene Stock analysis module also helps to analyze the Allogene Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Allogene Stock Analysis Notes

About 35.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 1.88. The entity had not issued any dividends in recent years. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was founded in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 301 people. For more info on Allogene Therapeutics please contact David Chang at 650 457 2700 or go to

Allogene Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Allogene Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Allogene Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Allogene Therapeutics generated a negative expected return over the last 90 days
Allogene Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 38.44 M. Net Loss for the year was (250.71 M).
Allogene Therapeutics currently holds about 483.48 M in cash with (149.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.39.
Allogene Therapeutics has a poor financial position based on the latest SEC disclosures
Roughly 63.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Allogene Therapeutics exotic insider transaction detected

Allogene Therapeutics Upcoming and Recent Events

Earnings reports are used by Allogene Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Allogene Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Earnings Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Allogene Largest EPS Surprises

Earnings surprises can significantly impact Allogene Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Allogene Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Allogene Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Allogene Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Allogene Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
18th of January 2022
Unclassified Corporate Event
15th of December 2021
Other Events. Entry into a Material Definitive Agreement
4th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
7th of October 2021
Other Events
17th of September 2021
Unclassified Corporate Event
4th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
2nd of August 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
15th of June 2021
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders

Allogene Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Allogene Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allogene Therapeutics backward and forwards among themselves. Allogene Therapeutics' institutional investor refers to the entity that pools money to purchase Allogene Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
First Hawaiian BankCommon Shares16.3 K243 K
Koshinski Asset Management IncCommon Shares200K
West Oak Capital LlcCommon Shares100.01000
Versant Capital Management IncCommon Shares15.00.0
Tpg Group Holdings Sbs Advisors IncCommon Shares18.7 M481 M
Blackrock IncCommon Shares7.3 M186.9 M
Vanguard Group IncCommon Shares6.7 M172.1 M
Note, although Allogene Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Allogene Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.68 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allogene Therapeutics's market, we take the total number of its shares issued and multiply it by Allogene Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Allogene Profitablity

Allogene Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Allogene Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Allogene Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Allogene Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Allogene Therapeutics' profitability requires more research than a typical breakdown of Allogene Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.26) (0.28) 
Return on Average Equity(0.29) (0.31) 
Return on Invested Capital(0.33) (0.36) 

Management Efficiency

The entity has return on total asset (ROA) of (13.65) % which means that it has lost $13.65 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (24.01) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics management efficiency ratios could be used to measure how well allogene therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to slide to -0.28. The value of Return on Average Equity is estimated to slide to -0.31. Allogene Therapeutics Goodwill and Intangible Assets are quite stable at the moment as compared to the past year. The company's current value of Goodwill and Intangible Assets is estimated at 139,476. Tangible Assets Book Value per Share is expected to rise to 11.01 this year, although the value of Total Assets will most likely fall to about 1.3 B.
Last ReportedProjected for 2022
Book Value per Share 8.07  9.79 
Enterprise Value over EBIT(14.95) (16.13) 
Enterprise Value over EBITDA(15.98) (17.24) 
Price to Book Value 2.95  3.37 
Tangible Assets Book Value per Share 9.18  11.01 
Enterprise Value3.9 B3.9 B
Tangible Asset Value1.4 B1.3 B

Technical Drivers

As of the 23rd of January, Allogene Therapeutics shows the mean deviation of 3.29, and Risk Adjusted Performance of (0.05). Allogene Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Allogene Therapeutics, which can be compared to its rivals. Please confirm Allogene Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Allogene Therapeutics is priced correctly, providing market reflects its regular price of 11.36 per share. Given that Allogene Therapeutics has jensen alpha of (0.27), we suggest you to validate Allogene Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Allogene Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Allogene Therapeutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Allogene Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allogene Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allogene Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allogene Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tpg Gp A Llc 2 days ago via Macroaxis 
Allogene Therapeutics exotic insider transaction detected
Arie Belldegrun over a week ago via Macroaxis 
Allogene Therapeutics exotic insider transaction detected
Amado Rafael over three months ago via Macroaxis 
Sale by Amado Rafael of 11507 shares of Allogene Therapeutics
Pf Equity Holdings 2 Bv over three months ago via Macroaxis 
Allogene Therapeutics exotic insider transaction detected
Bhavnagri Veer over three months ago via Macroaxis 
Exercise or conversion by Bhavnagri Veer of 5000 shares of Allogene Therapeutics subject to Rule 16b-3
Owen Witte over three months ago via Macroaxis 
Sale by Owen Witte of 5000 shares of Allogene Therapeutics
Owen Witte over three months ago via Macroaxis 
Sale by Owen Witte of 5000 shares of Allogene Therapeutics
Bhavnagri Veer over three months ago via Macroaxis 
Exercise or conversion by Bhavnagri Veer of 5000 shares of Allogene Therapeutics subject to Rule 16b-3
Bhavnagri Veer over three months ago via Macroaxis 
Sale by Bhavnagri Veer of 5000 shares of Allogene Therapeutics
Barrett Elizabeth A over three months ago via Macroaxis 
Acquisition by Barrett Elizabeth A of 63385 shares of Allogene Therapeutics subject to Rule 16b-3
Bhavnagri Veer over six months ago via Macroaxis 
Exercise or conversion by Bhavnagri Veer of 5000 shares of Allogene Therapeutics subject to Rule 16b-3
Bhavnagri Veer over six months ago via Macroaxis 
Exercise or conversion by Bhavnagri Veer of 5000 shares of Allogene Therapeutics subject to Rule 16b-3

Allogene Therapeutics Technical and Predictive Indicators

Allogene Therapeutics Forecast Models

Allogene Therapeutics time-series forecasting models is one of many Allogene Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Allogene Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Allogene Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Allogene Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Allogene shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Allogene Therapeutics. By using and applying Allogene Stock analysis, traders can create a robust methodology for identifying Allogene entry and exit points for their positions.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was founded in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 301 people.

Current Allogene Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Allogene analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Allogene analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Allogene Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Allogene analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Allogene stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Allogene Therapeutics, talking to its executives and customers, or listening to Allogene conference calls.
Allogene Analyst Advice Details

Allogene Stock Analysis Indicators

Allogene Therapeutics stock analysis indicators help investors evaluate how Allogene Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Allogene Therapeutics shares will generate the highest return on investment. By understating and applying Allogene Therapeutics stock analysis, traders can identify Allogene Therapeutics position entry and exit signals to maximize returns.
Quick Ratio9.22
Fifty Two Week Low11.54
Shares Short Prior Month5.67M
Average Daily Volume Last 10 Day2.01M
Average Daily Volume In Three Month1.43M
Shares Percent Shares Out3.95%
Gross Margins33.83%
Short Percent Of Float6.43%
Forward Price Earnings-4.55
Float Shares74.97M
Fifty Two Week High39.12
Enterprise Value To Ebitda-6.12
Fifty Day Average16.64
Two Hundred Day Average22.72
Enterprise Value To Revenue38.73
Please continue to Trending Equities. Note that the Allogene Therapeutics information on this page should be used as a complementary analysis to other Allogene Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Allogene Stock analysis

When running Allogene Therapeutics price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Allogene Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.